Background
Breast cancer is the most common cancer and cause of cancer-related death in women, and its incidence is positively correlated with age [
1,
2]. Approximately 50% of new breast cancer cases are recorded in women ≥ 60 years (
https://gco.iarc.fr/). However, treatment decisions for elderly patients with breast cancer are highly variable [
3,
4]. On the one hand, aging is accompanied by fragility and comorbidities [
5,
6]. On the other hand, prospective studies supporting specific treatments for elderly patients with breast cancer are lacking owing to ethical requirements [
7]. Therefore, no uniform treatment guidelines have been established for the elderly [
8,
9].
Some studies have been conducted in elderly patients with breast cancer whose primary option is surgery [
10]. The choice of surgical method is affected by age; that is, the acceptance rate of breast-conserving surgery decreases with age, and some studies have focused on the unwillingness of patients to receive the necessary radiotherapy after breast-conserving surgery [
11,
12]. Elderly patients exhibit a negative attitude toward their choice of treatment strategy, with a low reception of radiotherapy and chemotherapy. Among patients with indications for radiotherapy, only two thirds patients aged 71–80 years received this treatment [
13]. Many older patients receive inadequate chemotherapy treatment [
14]. A study showed that the proportion of patients aged ≥ 65 years with breast cancer who received a sufficient number of chemotherapy courses was significantly lower than that in younger patients (
P < 0.001 [
15]. Despite an understanding of breast cancer treatment in elderly individuals, clinicians still struggle to make appropriate treatment decisions for these individuals. To solve this problem, we analyzed the competing risks of breast cancer patients over 70 years of age using the Surveillance, Epidemiology, and End Results (SEER) database, identified independent predictors of breast cancer-specific death (BCSD), and constructed a nomogram of a predictive risk model to aid in clinical decision-making.
Discussion
Breast cancer is the most common malignant tumor and the main cause of death in elderly women [
19]. Despite comprising a large proportion of breast cancer cases, the elderly are underrepresented in clinical trials [
20], which is related to frailty in the elderly. Understanding the risk factors for BCSD in elderly patients with breast cancer could help comprehensively evaluate the status of patients and is of great importance for treatment decision-making.
The choice of treatment for elderly cancer patients is often complicated by the presence of multiple chronic comorbidities. When discussing the impact of breast cancer on the survival of older patients, deaths from other causes may occur before the event of interest, leading to the exclusion of relevant events. Considering this, a competing risk model was selected to address competing risk events.
In this study, we extracted information on 33,118 elderly patients with breast cancer from the SEER database and constructed a competitive risk model to screen 12 independent risk factors related to BCSD, making the results highly reliable. The probability of BCSD is correlated with age and tumor characteristics, such as molecular classification, tumor grade, and tumor stage. Compared to previous articles that included ten risk factors [
21], more risk factors were included in study that impact treatment choices, including radiation and chemotherapy, and BCSD in elderly patients. Elderly patients are likely to choose to forego chemotherapy and radiation because of the higher likelihood of adverse effects. We considered these two treatment approaches; thus, this nomogram can be an effective tool for predicting the CIF of patients with BCSD and appropriate treatment strategies.
In our study, we found that older age was an independent risk factor for higher BCSD probabilities. The inclusion of age as an independent predictive factor for the prognosis of patients with breast cancer has been a subject of ongoing controversy [
22]. For patients with breast cancer, especially those younger than 35 years old, younger age is associated with poor prognosis [
23,
24]. For elderly breast cancer patients, it is generally observed that the prognosis tends to worsen with increasing age, which is consistent with our results [
21,
25]. Regarding tumor factors, tumor stage and grade were important predictive risk factors, having a positive correlation with the CIF of BCSD, consistent with previously reported results [
26,
27].
Among these results, the effect of treatment on BCSD in elderly patients was our main focus. Among all treatment methods, surgery showed the greatest impact on BCSD in elderly patients, and this finding is similar to previous studies [
28‐
30]. One study showed that in early stage breast cancer, surgical treatment led to similar 5-year survival rates in both elderly and young patients [
28]. Some reports have also shown that age, comorbidities, cognition, functional status, and tumor size are correlated with the preference for operative treatment [
31]. With increasing age, few patients are recommended breast-conserving surgery, possibly because of clinicians’ concern that elderly patients cannot tolerate radiotherapy [
11,
32,
33]. However, our results suggest that patients who underwent mastectomy had a higher incidence of BCSD than those who underwent breast-conserving surgery.
In our analysis, chemotherapy significantly reduced the incidence of BCSD in elderly patients with breast cancer. Previous studies have reported that the toxicity and side effects of chemotherapy are severe, and the life expectancy of the elderly is short; therefore, the elderly are considered to benefit minimally from chemotherapy [
34]. In our study, only 15.4% of patients received chemotherapy, which is an extremely small proportion. Chemotherapy significantly reduces disease-free survival and prolongs overall survival in patients aged < 70 years old [
35]. In recent studies, chemotherapy was found to prolong disease-free survival and reduce the relative risk of recurrence among patients with breast cancer aged ≥ 65 years [
36]. In addition, chemotherapy has no significant effect on the cognitive function or quality of life in elderly patients receiving this treatment [
37,
38]. Therefore, chemotherapy is safe and suitable for elderly patients with breast cancer and has a negligible effect on their quality of life.
Our results show that radiotherapy is more effective than chemotherapy [
39,
40]. In early-stage, ER-positive patients aged > 70 years, adjuvant radiotherapy combined with endocrine therapy after breast-conserving surgery or mastectomy can significantly reduce the incidence of local recurrence but has no effect on overall survival [
41,
42]. In contrast, ER-negative patients with early-stage breast cancer have better overall survival when treated with radiotherapy [
43]. However, due to limited information in the database, regional radiotherapy and postoperative whole-breast radiotherapy cannot be distinguished; therefore, the impact of different radiotherapy modalities on outcomes could not be further analyzed when analyzing the effect of radiotherapy on BCSD. In general, radiotherapy may be recommended for disease control in elderly patients with a life expectancy of 5–10 years, radiotherapy might be recommended to control the disease [
44].
Using the SEER database, we constructed a nomogram to predict the CIF of BCSD in elderly patients in the 1st, 3rd, and 5th years after diagnosis. Compared with previous nomograms, our nomogram only focused on elderly patients and included additional clinical risk factors, particularly treatment modalities. Data on clinical factors can be collected from the medical histories at any time. The prediction accuracy of our nomogram was confirmed using the C-index and calibration curves, and the results proved that our nomogram is convenient and reliable. The use of a high-quality and large-sample database to conduct competitive risk analysis makes our study highly reliable.
In the future, clinicians may use this tool to accurately assess the prognosis of elderly patients with breast cancer and provide them with targeted and individualized treatments. Through this nomogram, patients can intuitively understand the benefits of different treatment methods and their prognoses. For example, based on our nomogram, the 1-, 3-, and 5-year BCSD of a 87-year-old patient, who is unmarried, white and with grade III triple-negative breast cancer staged T2 and N0, with partial mastectomy, was 3.84%, 20.5% and 34.7%, respectively.
However, this study has some limitations. Although an extremely small fraction, some cases with missing information were excluded from our analysis, possibly causing selection bias. In addition, our analysis was based on reported data, which may contain information bias. Finally, systemic treatments are being developed, and an increasing number of targeted drugs are being administered in clinics, both of which have a great impact on patient recovery. Although studies have shown that the use of endocrine therapy in elderly patients with breast cancer has become common practice [
45], our present work lacks data on endocrine therapy in these patients. Regardless, the lack of data on endocrine therapy did not affect the judgment of the overall results. Finally, the effect of comorbidities on prognosis was not considered in this study. To externally validate our nomogram, a large amount of data from prospective cohort studies is needed.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.